ArticleFrontiers in immunology2026

Development of immune-related adverse events is associated with improved survival outcomes in cancer patients receiving immune checkpoint inhibitors.

Faizah M Alotaibi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.